STOCK TITAN

Cryoport Reports Third Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cryoport (NASDAQ: CYRX) reported its Q3 2024 financial results. Life Sciences Services revenue increased by 9% YoY, with BioStorage/BioServices revenue up 12%. The company supported 691 global clinical trials as of September 30, 2024. Q3 2024 total revenue was $56.7 million, up 1% YoY. Life Sciences Products revenue fell by 14% YoY. The company reaffirmed its full-year 2024 revenue guidance of $225-$235 million. Gross margin improved to 44.8% from 43.2% YoY. Net income was $0.8 million for Q3 2024, compared to a net loss of $13.3 million in Q3 2023. Adjusted EBITDA was a negative $2.4 million, better than the negative $3.1 million in Q3 2023. Cryoport repurchased $175 million in Convertible Senior Notes due in 2026 for $154.5 million. The company launched IntegriCell™ Cryopreservation Solution in October 2024.

Cryoport (NASDAQ: CYRX) ha riportato i risultati finanziari per il terzo trimestre del 2024. I ricavi dei Servizi nelle Scienze della Vita sono aumentati del 9% rispetto all'anno precedente, con un incremento del 12% nei ricavi di BioStorage/BioServices. L'azienda ha supportato 691 studi clinici globali al 30 settembre 2024. I ricavi totali per il Q3 2024 sono stati di 56,7 milioni di dollari, in aumento dell'1% su base annua. I ricavi dei Prodotti nelle Scienze della Vita sono diminuiti del 14% rispetto all'anno precedente. L'azienda ha confermato le previsioni di ricavi per l'intero anno 2024, previste tra 225 e 235 milioni di dollari. Il margine lordo è migliorato al 44,8%, rispetto al 43,2% dell'anno precedente. L'utile netto è stato di 0,8 milioni di dollari per il Q3 2024, rispetto a una perdita netta di 13,3 milioni di dollari nel Q3 2023. L'EBITDA rettificato è stato negativo per 2,4 milioni di dollari, migliore rispetto ai -3,1 milioni di dollari del Q3 2023. Cryoport ha riacquistato 175 milioni di dollari in Note Convertibili Senior in scadenza nel 2026 per un totale di 154,5 milioni di dollari. L'azienda ha lanciato la soluzione di crioconservazione IntegriCell™ nel mese di ottobre 2024.

Cryoport (NASDAQ: CYRX) reportó sus resultados financieros para el tercer trimestre de 2024. Los ingresos de Servicios de Ciencias de la Vida aumentaron un 9% interanual, con ingresos de BioStorage/BioServices que aumentaron un 12%. La compañía apoyó 691 ensayos clínicos a nivel global al 30 de septiembre de 2024. Los ingresos totales del Q3 2024 fueron de 56,7 millones de dólares, un aumento del 1% en comparación con el año anterior. Los ingresos de Productos de Ciencias de la Vida cayeron un 14% interanual. La compañía reafirmó su guía de ingresos para el año completo 2024 de entre 225 y 235 millones de dólares. El margen bruto mejoró al 44,8%, frente al 43,2% del año anterior. La utilidad neta fue de 0,8 millones de dólares para el Q3 2024, en comparación con una pérdida neta de 13,3 millones de dólares en el Q3 2023. El EBITDA ajustado fue negativo en 2,4 millones de dólares, mejor que el negativo de 3,1 millones de dólares en el Q3 2023. Cryoport recompró 175 millones de dólares en Notas Senior Convertibles que vencen en 2026 por 154,5 millones de dólares. La compañía lanzó la Solución de Crioconservación IntegriCell™ en octubre de 2024.

크라이오포트 (NASDAQ: CYRX)는 2024년 3분기 재무 결과를 발표했습니다. 생명 과학 서비스 수익은 전년 대비 9% 증가했으며, 바이오스토리지/바이오서비스 수익은 12% 상승했습니다. 회사는 2024년 9월 30일 현재 691개의 글로벌 임상 시험을 지원했습니다. 2024년 3분기 총 수익은 5670만 달러로, 전년 대비 1% 증가했습니다. 생명 과학 제품 수익은 전년 대비 14% 감소했습니다. 회사는 2024년 전체 연도 수익 가이던스를 2억 2500만 달러에서 2억 3500만 달러로 재확인했습니다. 총 이익률은 전년 43.2%에서 44.8%로 개선되었습니다. 해당 분기의 순이익은 80만 달러로, 2023년 3분기의 1330만 달러 순손실과 비교되었습니다. 조정된 EBITDA는 -240만 달러로, 2023년 3분기의 -310만 달러보다 개선된 수치입니다. 크라이오포트는 2026년 만기 전환 시니어 노트 1억 7500만 달러를 1억 5450만 달러에 재매입했습니다. 회사는 2024년 10월에 인테그리셀™ 냉동 보존 용액을 출시했습니다.

Cryoport (NASDAQ: CYRX) a publié ses résultats financiers pour le troisième trimestre 2024. Les revenus des Services en Sciences de la Vie ont augmenté de 9% par rapport à l'année précédente, avec des revenus de BioStorage/BioServices en hausse de 12%. L'entreprise a soutenu 691 essais cliniques mondiaux au 30 septembre 2024. Les revenus totaux du T3 2024 s'élevaient à 56,7 millions de dollars, en hausse de 1% par rapport à l'année précédente. Les revenus des Produits en Sciences de la Vie ont chuté de 14% par rapport à l'année précédente. L'entreprise a confirmé ses prévisions de revenus pour l'année entière 2024, qui se situent entre 225 millions et 235 millions de dollars. La marge brute a augmenté à 44,8% par rapport à 43,2% l'année précédente. Le bénéfice net s'élevait à 0,8 million de dollars pour le T3 2024, contre une perte nette de 13,3 millions de dollars au T3 2023. L'EBITDA ajusté était de -2,4 millions de dollars, mieux que les -3,1 millions de dollars du T3 2023. Cryoport a racheté pour 175 millions de dollars de Obligations Senior Convertibles arrivant à échéance en 2026 pour 154,5 millions de dollars. L'entreprise a lancé la Solution de Cryoconservation IntegriCell™ en octobre 2024.

Cryoport (NASDAQ: CYRX) hat seine finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht. Der Umsatz im Bereich Lebenswissenschaftliche Dienstleistungen stieg im Jahresvergleich um 9%, während der Umsatz von BioStorage/BioServices um 12% zunahm. Das Unternehmen unterstützte bis zum 30. September 2024 insgesamt 691 globale klinische Studien. Der Gesamtumsatz im Q3 2024 belief sich auf 56,7 Millionen USD, was einem Anstieg von 1% im Vergleich zum Vorjahr entspricht. Der Umsatz im Bereich Lebenswissenschaftliche Produkte fiel im Jahresvergleich um 14%. Das Unternehmen bestätigte die Umsatzprognose für das Gesamtjahr 2024 in Höhe von 225 bis 235 Millionen USD. Die Bruttomarge verbesserte sich von 43,2% auf 44,8% im Vergleich zum Vorjahr. Der Nettogewinn betrug im Q3 2024 0,8 Millionen USD im Vergleich zu einem Nettoverlust von 13,3 Millionen USD im Q3 2023. Das ajustierte EBITDA betrug -2,4 Millionen USD und war besser als die -3,1 Millionen USD im Q3 2023. Cryoport hat Schuldverschreibungen in Höhe von 175 Millionen USD, die 2026 fällig werden, für 154,5 Millionen USD zurückgekauft. Das Unternehmen brachte im Oktober 2024 die IntegriCell™ Kryokonservierungslösung auf den Markt.

Positive
  • Life Sciences Services revenue up 9% YoY.
  • BioStorage/BioServices revenue up 12% YoY.
  • Gross margin improved to 44.8%.
  • Net income of $0.8 million for Q3 2024.
  • Company reaffirmed full-year 2024 revenue guidance of $225-$235 million.
  • Repurchased $175 million in Convertible Senior Notes for $154.5 million.
Negative
  • Life Sciences Products revenue down 14% YoY.
  • Adjusted EBITDA was a negative $2.4 million.
  • Total revenue for 9M 2024 down 4% YoY.
  • Net loss attributable to common stockholders of $102.1 million for 9M 2024.

Insights

Cryoport's Q3 2024 results show mixed performance with some concerning trends. While Life Sciences Services revenue grew 9% year-over-year, Life Sciences Products revenue declined -14%. The company maintained full-year revenue guidance of $225-235 million but faces ongoing sector challenges.

Key positives include improved gross margins to 44.8% and a return to net income of $0.8 million in Q3. The company's strategic debt management through $175 million convertible note repurchases and strong cash position of $272.7 million provide financial flexibility.

However, the $63.8 million goodwill impairment from Q2 and negative adjusted EBITDA of $2.4 million raise concerns about operational efficiency. The company's support of 691 clinical trials and 17 commercial therapies suggests future growth potential, but near-term headwinds persist.

The biotech sector dynamics significantly impact Cryoport's performance. The company's strategic positioning in cell & gene therapy logistics shows promise with 12% growth in BioStorage/BioServices, but broader market challenges are evident in product sales decline.

The pipeline of 691 clinical trials, including 79 in Phase 3 and anticipated regulatory filings suggest strong future demand. However, current commercial therapy revenue at $6.1 million (11% of total) indicates dependency on clinical trial success for growth. The launch of IntegriCell™ and focus on profitable growth align with market needs but may take time to materialize into significant revenue.

  • Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year
  • Supported a record total of 691 global clinical trials as of September 30, 2024
  • Company reaffirmed full year 2024 revenue guidance of $225 to $235 million

NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024. 

Jerrell Shelton, CEO of Cryoport, remarked, "Our Life Sciences Services business showed 9% growth during the third quarter, with BioStorage/BioServices revenue increasing by 12% compared to the third quarter of last year. The increase in our services revenue was coupled with a substantial improvement in gross margin to 46% for our services business.

"Reflecting on our performance through the third quarter, we are maintaining our full-year revenue forecast of $225 million to $235 million, anticipating continued growth in our services business while acknowledging the ongoing softness in product sales.

"We have been actively executing on our cost reduction and capital realignment strategies and we are currently on course to complete these adjustments by the year's end. These actions are already showing positive results, as evidenced by the improvement in our gross margin, adjusted EBITDA and positive cash flow this quarter, moving us closer towards our objective of sustainable profitability. We believe that these measures will lead us to a return to positive adjusted EBITDA during 2025.

"We expect the macroeconomic and sector-specific challenges that have impacted many companies serving the life sciences industry to continue for the near future, so we plan to further sharpen our focus on profitable growth and maintaining a strong balance sheet. We continue to be optimistic about our long-term business growth trajectory. We believe that we are strategically positioned to leverage the anticipated long-term growth in the Life Sciences and the Cell & Gene Therapy market through our comprehensive and integrated supply chain solutions.

"In October, we launched our IntegriCell™ Cryopreservation Solution with a new state-of-the-art facility on our Houston campus. This offering addresses yet another critical aspect in optimizing the supply chain for the development and commercialization of cell-based therapies through high quality, standardized, cryopreserved starting material," Mr. Shelton concluded.

In tabular form, Q3 2024 and 9M 2024 revenue compared to Q3 2023 and 9M 2023, respectively, was as follows:

Cryoport, Inc. and Subsidiaries







Revenue 







(unaudited)








Three Months Ended
September 30,

Nine Months Ended
September 30,

(in thousands)

2024

2023

% Change

2024

2023

% Change

Life Sciences Services

$       39,278

$       36,022

9 %

$     114,104

$     107,062

7 %

BioLogistics Solutions

35,302

32,486

9 %

103,076

97,093

6 %

BioStorage/BioServices 

3,976

3,536

12 %

11,028

9,969

11 %

Life Sciences Products

$       17,386

$       20,135

-14 %

$       54,749

$       68,933

-21 %

Total Revenue

$       56,664

$       56,157

1 %

$     168,853

$     175,995

-4 %

 

BioStorage/BioServices revenue continues to grow double digits year-over-year, increasing 12%, as we continue to introduce our expanded capabilities to existing customers as well as add new customers into our global network, and as more allogeneic clinical and commercial therapies progress in the number of patients treated.

Revenue from commercially approved Cell & Gene therapies represented $6.1 million, or 11%, of total revenue for Q3 2024. During Q3 2024, one new therapy was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, which was SanBio's AKUUGO, an allogeneic treatment for the indication of improving chronic motor paralysis resulting from traumatic brain injury. In addition, the FDA approved Adaptimmune's Tecelra for the treatment of adults with unresectable or metastatic synovial sarcoma, the first cell therapy targeting a solid tumor. Our total commercial therapy count was seventeen (17) as of September 30, 2024.

As of September 30, 2024, Cryoport supported a total of 691 global clinical trials, a net increase of 21 clinical trials over September 30, 2023, with 79 trials in Phase 3. The number of trials by phase and region are as follows: 

Cryoport Supported Clinical Trials by Phase


Clinical Trials

September 30,

2022

2023

2024

Phase 1

268

275

295

Phase 2

295

314

317

Phase 3

80

81

79

Total

643

670

691





Cryoport Supported Clinical Trials by Region


Clinical Trials

September 30,

2022

2023

2024

Americas

496

516

531

EMEA

105

112

112

APAC

42

42

48

Total

643

670

691

  

During the third quarter, three (3) Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings occurred, and one (1) BLA filing occurred in October. For the remainder of 2024, we anticipate up to an additional four (4) application filings and two (2) new therapy approvals, with another two (2) possible approvals of new therapies in January of 2025.

BioLogistics Solutions revenue rose 9% year over year during the third quarter as it continued to benefit from the ramp in temperature-controlled logistics revenue outside of the Cell & Gene therapy market, including biosimilars, antibodies, APIs and a growing number of Direct-to-Patient shipments.

Financial Highlights

Revenue

  • Total revenue for Q3 2024 was $56.7 million compared to $56.2 million for Q3 2023, a year-over-year increase of 1% or $0.5 million
    • Life Sciences Services revenue for Q3 2024 was $39.3 million compared to $36.0 million for Q3 2023, up 9.0% year-over-year and 3.3% sequentially, including BioStorage/BioServices revenue of $4.0 million, up 12.4% year-over-year and 12.9% sequentially
    • Life Sciences Products revenue for Q3 2024 was $17.4 million compared to $20.1 million for Q3 2023, down 13.7% year-over-year and 11.1% sequentially.
  • Total revenue for 9M 2024 was $168.9 million compared to $176.0 million for 9M 2023.
    • Life Sciences Services revenue for 9M 2024 was $114.1 million compared to $107.1 million for 9M 2023, including BioStorage/BioServices revenue of $11.0 million for 9M 2024 compared to $10.0 million for 9M 2023.
    • Life Sciences Products revenue for 9M 2024 was $54.7 million compared to $68.9 million for 9M 2023.

Gross Margin

  • Total gross margin was 44.8% for Q3 2024 compared to 43.2% for Q3 2023. 
    • Gross margin for Life Sciences Services was 46.0% for Q3 2024 compared to 42.2% for Q3 2023.
    • Gross margin for Life Sciences Products was 42.1% for Q3 2024 compared to 44.9% for Q3 2023.
  • Total gross margin was 42.8% for 9M 2024 compared to 43.2% for 9M 2023.
    • Gross margin for Life Sciences Services was 44.0% for 9M 2024 compared to 44.1% for 9M 2023.
    • Gross margin for Life Sciences Products was 40.5% for 9M 2024 compared to 41.9% for 9M 2023.

Operating Costs and Expenses

  • Operating costs and expenses were $41.8 million for Q3 2024 compared to operating costs and expenses of $41.2 million for Q3 2023. Operating costs and expenses for 9M 2024 were $189.3 million compared to $121.4 million for 9M 2023. The operating costs and expenses for 9M 2024 include an impairment loss of $63.8 million recorded in Q2 2024, which is primarily related to the write off of remaining goodwill for MVE Biological Solutions.

Net Income (Loss)

  • Net income was $0.8 million for Q3 2024 compared to a net loss of $13.3 million for Q3 2023, which was primarily a result of increased gains on the extinguishment of debt. Net loss was $96.1 million for 9M 2024 compared to a net loss of $37.2 million for the same period in 2023, which was primarily a result of the impairment loss of $63.8 million recorded in Q2 2024.
  • Net loss attributable to common stockholders was $1.2 million, or $0.02 per share, and $102.1 million, or $2.07 per share, for Q3 2024 and 9M 2024, respectively. This compares to a net loss attributable to common stockholders of $15.3 million, or $0.31 per share, and $43.2 million, or $0.89 per share, for Q3 2023 and 9M 2023, respectively.

Adjusted EBITDA

  • Adjusted EBITDA was a negative $2.4 million for Q3 2024, compared to a negative $3.1 million for Q3 2023. Adjusted EBITDA for 9M 2024 was a negative $13.9 million, compared to a negative $1.7 million for 9M 2023.

Cash, Cash equivalents, and Short-Term Investments

  • Cryoport held $272.7 million in cash, cash equivalents, and short-term investments as of September 30, 2024.

Convertible Debt repurchases

  • In Q3 2024, the Company announced that its Board of Directors had authorized a repurchase program to purchase up to $200.0 million of the Company's common stock and/or convertible senior notes (the "2024 Repurchase Program"), which was in addition to the remaining amount under its 2022 repurchase program. The 2024 Repurchase Program became effective on August 1, 2024, and remains in effect through December 31, 2027. The Company has approximately $73.9 million in total of repurchase authorization available under its two Repurchase Programs as of September 30, 2024.
  • During Q3 2024, the Company repurchased $175.0 million in aggregate principal amount of its Convertible Senior Notes due in 2026 for an aggregate repurchase price of $154.5 million.

Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Outlook

The Company reaffirms full year 2024 revenue guidance in the range of $225 million - $235 million. The Company's 2024 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of our control, such as the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, and the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.

Additional Information

Further information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance are provided in the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which is expected to be filed with the SEC on November 7, 2024. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com.

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to the earnings release, a document titled "Cryoport Third Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Thursday, November 7, 2024. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference call at 5:00 p.m. ET on November 7, 2024. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.

Conference Call Information

Date:

Thursday, November 7, 2024

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the "Cryoport Call" or Conference ID: 1171580

Live webcast:

'Investor Relations' section at www.cryoportinc.com or click here.

 

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until November 14, 2024. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1171580#.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to conduct their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.

Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport's anticipation of continued growth in its services business and ongoing softness in product sales; Cryoport's plans and expectations relating to its previously announced cost reduction and capital realignment strategies, including Cryoport's plans to complete these adjustments by the year's end and Cryoport's belief that these measures will lead to a return to positive adjusted EBITDA during 2025; Cryoport's expectations that the macroeconomic and sector-specific challenges that have impacted many companies serving the life sciences industry to continue into the near future; and Cryoport's belief that it is strategically positioned to leverage the anticipated long-term growth in the Cell & Gene therapy market through Cryoport's comprehensive and integrated supply chain solutions. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties include difficulties, delays or Cryoport's inability to successfully complete its planned cost reduction and capital realignment measures, which could reduce the benefits realized from such activities within the time periods currently anticipated. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.






Cryoport, Inc. and Subsidiaries





Condensed Consolidated Statements of Operations






Three Months Ended
September 30,
(unaudited)

Nine Months Ended
September 30,
(unaudited)

(in thousands, except share and per share data)

2024

2023

2024

2023

Revenue





Life Sciences Services revenue

$              39,278

$              36,022

$            114,104

$            107,062

Life Sciences Products revenue

17,386

20,135

54,749

68,933

Total revenue

56,664

56,157

168,853

175,995

Cost of revenue:





Cost of services revenue

21,220

20,803

63,927

59,887

Cost of products revenue

10,059

11,088

32,576

40,037

Total cost of revenue

31,279

31,891

96,503

99,924

Gross margin

25,385

24,266

72,350

76,071

Operating costs and expenses:





Selling, general and administrative

37,654

36,023

111,921

108,066

Engineering and development

4,157

5,152

13,555

13,291

Impairment loss

-

-

63,809

-

Total operating costs and expenses:

41,811

41,175

189,285

121,357

Loss from operations

(16,426)

(16,909)

(116,935)

(45,286)

Other income (expense):





Investment income

3,059

2,848

8,468

7,962

Interest expense

(889)

(1,357)

(3,472)

(4,197)

Gain on extinguishment of debt, net

17,326

5,679

18,505

5,679

Other income (expense), net

(1,616)

(3,059)

(1,398)

242

Income (loss) before provision for income taxes

1,454

(12,798)

(94,832)

(35,600)

Provision for income taxes

(649)

(471)

(1,247)

(1,598)

Net income (loss)

$                    805

$             (13,269)

$             (96,079)

$             (37,198)

Paid-in-kind dividend on Series C convertible preferred stock

(2,000)

(2,000)

(6,000)

(6,000)

Net loss attributable to common stockholders

$               (1,195)

$             (15,269)

$          (102,079)

$             (43,198)

Net loss per share attributable to common stockholders - basic and diluted

$                 (0.02)

$                 (0.31)

$                 (2.07)

$                 (0.89)

Weighted average common shares outstanding - basic and diluted

49,417,757

48,904,102

49,261,717

48,660,646

 

Cryoport, Inc. and Subsidiaries



Condensed Consolidated Balance Sheets




September 30,

December 31,


2024

2023

(in thousands)

(unaudited)


Current assets



Cash and cash equivalents

$                      44,665

$                      46,346

Short-term investments

228,001

410,409

Accounts receivable, net

43,461

42,074

Inventories

23,552

26,206

Prepaid expenses and other current assets

10,658

10,077

Total current assets

350,337

535,112

Property and equipment, net

88,281

84,858

Operating lease right-of-use assets

30,113

32,653

Intangible assets, net

175,815

194,382

Goodwill

54,057

108,403

Deposits

1,493

1,680

Deferred tax assets

1,669

656

 Total assets 

$                    701,765

$                    957,744




Current liabilities



Accounts payable and other accrued expenses

$                      25,194

$                      26,995

Accrued compensation and related expenses

11,275

11,409

Deferred revenue

1,091

1,308

Current portion of operating lease liabilities

5,834

5,371

Current portion of finance lease liabilities

470

286

Current portion of convertible senior notes, net

14,271

-

Current portion of notes payable

153

149

Current portion of contingent consideration

3,151

92

Total current liabilities

61,439

45,610

Convertible senior notes, net

183,628

378,553

Notes payable, net

1,238

1,335

Operating lease liabilities, net

26,466

29,355

Finance lease liabilities, net

1,306

954

Deferred tax liabilities

3,526

2,816

Other long-term liabilities

569

601

Contingent consideration, net

5,021

9,497

    Total liabilities

283,193

468,721

    Total stockholders' equity

418,572

489,023

    Total liabilities and stockholders' equity

$                    701,765

$                    957,744

 

Note Regarding Use of Non-GAAP Financial Measures

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 are included in this release: revenue at constant currency, revenue growth rate at constant currency, operating costs and expenses, excluding impairment loss, net income, excluding impairment loss, and adjusted EBITDA. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including revenue at constant currency, revenue growth rate at constant currency and adjusted EBITDA, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

We believe that revenue growth is a key indicator of how Cryoport is progressing from period to period, and we believe that the non-GAAP financial measures, revenue at constant currency and revenue growth rate at constant currency, are useful to investors in analyzing the underlying trends in revenue. Under GAAP, revenue received in local (non-U.S. dollar) currency is translated into U.S. dollars at the average exchange rate for the period presented. As a result, fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities, which in turn may adversely affect results of operations and cash flows and the comparability of period-to-period results of operations. When we use the term "constant currency," it means that we have translated local currency revenue for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenue into U.S. dollars that we used to translate local currency revenue for the comparable reporting period of the prior year. Revenue growth rate at constant currency refers to the measure of comparing the current reporting period revenue at constant currency with the reported GAAP revenue for the comparable reporting period of the prior year.

However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both period-over-period changes in non-GAAP constant currency revenue on the one hand and changes in revenue prepared in accordance with GAAP on the other. We caution the readers of this press release to follow a similar approach by considering revenue on constant currency period-over-period changes only in addition to, and not as a substitute for, or superior to, changes in revenue prepared in accordance with GAAP.

Operating costs and expenses, excluding impairment loss, is defined as operating costs and expenses, excluding impairment losses, if any. Net loss, excluding impairment loss, is defined as net loss, excluding impairment losses, if any. Management believes these measures, when read in conjunction with, and as supplemental to, the corresponding GAAP financial measures, provide a useful measure of Cryoport's expenses and operating results, a meaningful comparison with historical results, and insight into Cryoport's operating performance.

Adjusted EBITDA is defined as net loss adjusted for interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency (gain)/loss, gain on insurance claim, net gain on extinguishment of debt, impairment loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes that adjusted EBITDA provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company's board of directors utilize adjusted EBITDA to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.

Cryoport, Inc. and Subsidiaries





Reconciliation of GAAP operating cost and expenses to Non-GAAP adjusted operating cost and expenses

(unaudited)






Three Months Ended
September 30,

Nine Months Ended
September 30,


2024

2023

2024

2023

(in thousands)





GAAP operating costs and expenses

$        41,811

$             41,175

$      189,285

$      121,357

Non-GAAP adjustments to operating costs and expenses





Impairment loss

63,809

Non-GAAP adjusted operating costs and expenses

$        41,811

$             41,175

$      125,476

$      121,357






Cryoport, Inc. and Subsidiaries





Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)



(unaudited)






Three Months Ended
September 30,

Nine Months Ended
September 30,


2024

2023

2024

2023

(in thousands)





GAAP net income (loss)

$              805

$           (13,269)

$      (96,079)

$      (37,198)

Non-GAAP adjustments to net income (loss)





Impairment loss

63,809

Non-GAAP adjusted net income (loss)

$              805

$           (13,269)

$      (32,270)

$      (37,198)

 

Cryoport, Inc. and Subsidiaries





Reconciliation of GAAP net income (loss) to adjusted EBITDA




(unaudited)






Three Months Ended
September 30,

Nine Months Ended
September 30,


2024

2023

2024

2023

(in thousands)





GAAP net income (loss)

$              805

$      (13,269)

$      (96,079)

$      (37,198)

Non-GAAP adjustments to net income (loss):





Depreciation and amortization expense

7,836

6,911

22,863

20,038

Acquisition and integration costs

308

675

896

6,304

Cost reduction initiatives

568

1,116

Investment income

(3,059)

(2,848)

(8,468)

(7,962)

Unrealized loss on investments

3,535

2,336

2,593

2,300

Gain on insurance claim

(2,642)

Foreign currency (gain)/loss

(1,724)

710

(762)

114

Interest expense, net

889

1,357

3,472

4,197

Stock-based compensation expense

4,838

5,976

15,291

16,960

Gain on extinguishment of debt, net

(17,326)

(5,679)

(18,505)

(5,679)

Impairment loss

63,809

Change in fair value of contingent consideration

316

250

(1,329)

250

Other non-recurring costs

Income taxes

649

471

1,247

1,598

Adjusted EBITDA

$         (2,365)

$         (3,110)

$      (13,856)

$         (1,720)

 

Cryoport, Inc. and Subsidiaries




Total revenue by type for the three months ended September 30, 2024

(unaudited)





Life Sciences
Services

Life Sciences
Products

Total

(in thousands)




As Reported

$             39,278

$                17,386

$             56,664

Non US-GAAP Constant Currency

39,193

17,340

56,532

FX Impact [$]

85

46

132

FX Impact [%]

0.2 %

0.3 %

0.2 %









Cryoport, Inc. and Subsidiaries




Total revenue by type for the nine months ended September 30, 2024

(unaudited)





Life Sciences
Services

Life Sciences
Products

Total

(in thousands)




As Reported

$           114,104

$                54,749

$           168,853

Non US-GAAP Constant Currency

114,220

54,774

168,994

FX Impact [$]

(116)

(25)

(141)

FX Impact [%]

(0.1 %)

(0.0 %)

(0.1 %)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-third-quarter-2024-financial-results-302299246.html

SOURCE Cryoport, Inc.

FAQ

What was Cryoport's Q3 2024 revenue?

Cryoport's Q3 2024 revenue was $56.7 million, a 1% increase year-over-year.

How did Cryoport's Life Sciences Services perform in Q3 2024?

Life Sciences Services revenue increased by 9% year-over-year in Q3 2024.

What is Cryoport's full-year 2024 revenue guidance?

Cryoport reaffirmed its full-year 2024 revenue guidance of $225-$235 million.

How did Cryoport's Life Sciences Products revenue perform in Q3 2024?

Life Sciences Products revenue decreased by 14% year-over-year in Q3 2024.

What was Cryoport's net income for Q3 2024?

Cryoport reported a net income of $0.8 million for Q3 2024.

What are the details of Cryoport's Convertible Senior Notes repurchase?

Cryoport repurchased $175 million in Convertible Senior Notes due in 2026 for an aggregate price of $154.5 million.

CryoPort, Inc.

NASDAQ:CYRX

CYRX Rankings

CYRX Latest News

CYRX Stock Data

324.14M
48.15M
2.5%
101.82%
5.88%
Integrated Freight & Logistics
Pharmaceutical Preparations
Link
United States of America
BRENTWOOD